Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Feb 17, 2020
SOUTH PLAINFIELD, N.J. , Feb. 17, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year-end 2019 financial results and provide an update on the company's business and outlook on
Additional Formats
Feb 06, 2020
- Statistically significant results in primary and key secondary endpoints - - Risdiplam is the first SMA treatment to have positive placebo-controlled data in pivotal studies across a real world population of infants, children, teenagers and adults - - Investor call at 8am ET - SOUTH PLAINFIELD,
Additional Formats
Feb 03, 2020
SOUTH PLAINFIELD, N.J. , Feb. 3, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on January 29, 2020 it approved non-statutory stock options to purchase an aggregate of 182,150 shares of its common stock to 57 new employees.
Additional Formats
Feb 03, 2020
SOUTH PLAINFIELD, N.J. , Feb. 3, 2020 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will host a conference call on Thursday, February 6, 2020 , at 8:00 am ET highlighting data on risdiplam in type 2/3 spinal muscular atrophy patients from part 2 of the
Additional Formats
Feb 03, 2020
- STRIDE registry analysis shows Translarna preserved ambulation and physical function by years compared with those in CINRG Duchenne Natural History Study, with no new safety signals1- - Trend toward delayed worsening of pulmonary function compared with natural history study1- SOUTH PLAINFIELD,
Additional Formats
Jan 23, 2020
- Study meets primary endpoint in patients living with type 1 SMA - - To date, more than 400 patients have been treated with risdiplam across all studies, with no treatment related safety findings leading to study withdrawal in any risdiplam trial - - Risdiplam PDUFA expected May 24, 2020 - SOUTH
Additional Formats
Jan 13, 2020
- PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020 - - 3 clinical trials from PTC's new redox platform to begin in 2020 - - ~ $306 million preliminary unaudited 2019 total revenue - - 2020 Duchenne franchise revenue guidance of $320-340 million - SOUTH PLAINFIELD, N.J. , Jan.
Additional Formats
Jan 06, 2020
SOUTH PLAINFIELD, N.J. , Jan. 6, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 th at 8:30 a.m. PST .
Additional Formats
Dec 13, 2019
SOUTH PLAINFIELD, N.J. , Dec. 13, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on December 9, 2019 it approved non-statutory stock options to purchase an aggregate of 59,150 shares of its common stock to 17 new employees.
Additional Formats
Nov 29, 2019
SOUTH PLAINFIELD, N.J. , Nov. 29, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on November 25, 2019 it approved non-statutory stock options to purchase an aggregate of 144,550 shares of its common stock to 36 new employees.
Additional Formats